Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.
ROCKVILLE, Md. (BUSINESS WIRE) GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations o.
GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American.
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.36 and traded as high as $1.53. GlycoMimetics shares last traded at $1.53, with a volume of 79,729 shares. Analyst Ratings Changes Several research analysts recently weighed in […]